Case Study | December 15, 2011

An MRI-guided prostate biopsy results in a fortunate outcome for this prostate cancer survivor.

An MRI-guided prostate biopsy showed the presence of cancer for this patient a previous TRUS biopsy was negative.

At 59, George LaVie (not his real name) faced an uncertain future. Based on rising PSA levels (prostate-specific antigen), he had undergone a transrectal ultrasound biopsy (TRUS) to attempt to determine the presence of disease. The results were negative.  

George’s story is not unusual. Rising PSA levels are a potential indicator of prostate disease. The standard course of action is a TRUS biopsy. Ultrasound guides the urologist, who takes up to 12 core samples from the gland. In George’s case, the results gave no indication of cancer, so he began “watchful waiting.”

“I went another year or so and my PSA levels continued to rise,” says George. “My urologist recommended that I get another biopsy. I was apprehensive about doing that. ”  

Prompted by George’s rising PSA levels and previous negative TRUS biopsy, an alternative imaging modality was considered. A plan was devised to use new MRI-guided prostate biopsy technology to get better anatomical definition and possibly reach a more conclusive diagnosis. One of the key selling points for George was that, with a better indication of the suspect areas, fewer biopsy samples may be required.

George agreed to try the procedure and was sent to Desert Medical Imaging of Indian Wells, Calif., for a diagnostic MRI. An initial MRI indicated there was indeed something in the prostate that didn’t look right, some sort of mass.  

George’s urologist, working side by side with Dr. John Feller of Desert Medical Imaging, performed an MRI-guided prostate biopsy. Five samples were taken during the 30-minute procedure, and subsequent pathology results conclusively showed the presence of cancer.

“I chose to have a radical prostatectomy,” says George. “They removed the prostate and felt that there was no surrounding tissue that was affected by the cancer, so they gave me a good prognosis.”

He continues, “Quite frankly, if this new procedure hadn’t been available, I may have chosen to wait and see and not even have had the biopsy done. And if I had waited, there’s no telling where the cancer would have spread.”

Case study supplied by Invivo Corp.

Related Content

News | Radiation Therapy

October 19, 2021 — RAD Technology Medical Systems (RAD) announced that it will be exhibiting at the 2021 American ...

Time October 19, 2021
arrow
News | PET Imaging

October 19, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 19, 2021
arrow
News | Ultrasound Women's Health

October 14, 2021 — In a first-in-world clinical trial, researchers at Sunnybrook Health Sciences Centre in Toronto ...

Time October 14, 2021
arrow
News | Lung Imaging

October 11, 2021 — According to ARRS’ American Journal of Roentgenology (AJR), percutaneous image-guided microwave and ...

Time October 11, 2021
arrow
News | Women's Health

October 8, 2021 — An analysis of nearly 200,000 patients who received mammograms between 2006 and 2015 across three U.S ...

Time October 08, 2021
arrow
News | Radiation Therapy

October 7, 2021 — NANOBIOTIX, a late-stage clinical biotechnology company pioneering physics-based approaches to expand ...

Time October 07, 2021
arrow
News | Radiation Therapy

October 7, 2021 — ViewRay, Inc. announced that the company has received acceptance from the FDA on their recent ...

Time October 07, 2021
arrow
News | Women's Health

October 5, 2021 — A promising radionuclide treatment may offer new therapeutic options for breast cancer patients ...

Time October 05, 2021
arrow
Feature | Radiation Therapy | By Dave Fornell

To maintain safety in radiation therapy (RT), every machine performance and patient delivery measurement must be as ...

Time October 05, 2021
arrow
News | Radiation Oncology

September 28, 2021 — The global radiotherapy devices market is expected to grow from $5.44 billion in 2020 to $5.848 ...

Time September 28, 2021
arrow
Subscribe Now